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Amyloid imaging using positron emission tomography (PET) has an emerging role in the 
management of Alzheimer’s disease (AD). The basis of this imaging is grounded on the fact that 
the hallmark of AD is the histological detection of beta amyloid plaques (Aβ) at post mortem 
autopsy. Currently, there are three FDA approved amyloid radiotracers used in clinical practice. 
This review aims to take the readers through the array of various indications for performing 
amyloid PET imaging in the management of AD, particularly using 18F-labelled 
radiopharmaceuticals. We elaborate on PET amyloid scan interpretation techniques, their 
limitations and potential improved specificity provided by interpretation done in tandem with 
genetic data such as apolipiprotein E (APO) 4 carrier status in sporadic cases and molecular 
information (e.g., cerebral spinal fluid (CSF) amyloid levels). We also describe the quantification 
methods such as the standard uptake value ratio (SUVr) method that utilizes various cutoff points 
for improved accuracy of diagnosing AD, such as a threshold of 1.122 (area under the curve 
0.894), which has a sensitivity of 92.3% and specificity of 90.5%, whereas the cutoff points may 
be higher in APOE ε4 carriers (1.489) compared to non-carriers (1.313). Additionally, 
recommendations for future developments in this field are also provided.  
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